science wire

Zykadia (ceritinib) demonstrated an overall response rate of 54.6% in patients with ALK+ metastatic NSCLC who have no other treatment option Median duration of response to Zykadia was 7&period

CHMP has recognized Gilenya's favorable benefit/risk profile and recommends EU label expansion to patients not responding to DMTs beyond interferon AAN data: Gilenya reduces relapse rates, new MRI lesion counts, brain volume loss & disability progression in pre-treated MS patients with high disease activity Gilenya is the only oral DMT that is effective across four key measures of MS (relapse rates, MRI lesions, brain volume loss and disabil

FDA Approves Roche's HPV Test for First-Line Primary Screening for Cervical Cancer Expanded indication makes cobas HPV Test the only test approved in U.S. that can be used instead of Pap in first-line primary screening in women 25 and older Roche announced today that the U.S. Food and Drug Administration (FDA) approved the cobas HPV (Human Papillomavirus) Test for use as a first-line primary screening test for cervical cancer in women 25 and older.

Results confirm non-inferiority of Onbrez Breezhaler (indacaterol) in lung function compared to Seretide * (salmeterol/fluticasone) in the studied population In INSTEAD study, patients with moderate COPD and no exacerbations in the past year were switched from salmeterol/fluticasone to Onbrez Breezhaler Study showed similar symptomatic benefits in terms of shortness of breath and health status in patients treated with Onbrez Breezhaler compared

Net sales of USD 14.0 billion up 1% (+3% cc ) with all divisions contributing to growth (cc); core operating leverage (cc) driven by Pharmaceuticals and lower Corporate costs Operating income

Gilenya reduced relapse rates, new MRI lesion counts, brain volume loss and disability progression in previously-treated MS patients with high disease activity Data at AAN showed significantly more Gilenya-treated patients (vs.

Acquires GSK oncology products, strengthening Novartis' leading Oncology business with novel therapies and becomes GSK's preferred commercialization partner for its oncology pipeline Combines Novarti

Basel, April 9, 2014 - Novartis announced today the appointment of Jeff George as Division Head of Alcon, effective May 1, 2014.

The designation highlights the potential of Bexsero to meet the urgent need for a licensed vaccine in the US against unpredictable and devastating meningitis B Bexsero, already approved in Europe, Ca

One million antimalarial treatments donated by Novartis, matching one million treatments funded through Malaria No More's Power of One campaign Power of One enables the public to fund malaria tests a

More than 50 abstracts highlight breadth and depth of Novartis Oncology pipeline and ability to test various combinations early to target multiple pathways Data show activity of investigational compo

Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Novartis study published in NEJM showed LDK378 demonstrated an overall response rate of 58% in patients with ALK+ NSCLC Data showed investigational treatment LDK378 (ceritinib) also achieved a median progression-free survival of seven months Patients with this type of lung cancer, especially those for whom prior therapies have failed, are in need of new treatment options Data served as the basis for regulatory application to the US Food and Drug

New phase III psoriasis data show rapid, significant skin clearance and convenient administration with Novartis' secukinumab (AIN457) Pivotal phase III FEATURE and JUNCTURE studies met primary and pre-specified secondary endpoints, showing high efficacy with convenient pre-filled syringe (PFS) and autoinjector/pen (AI) , Patient-reported outcomes from FEATURE and JUNCTURE show high patient satisfaction with secukinumab PFS and AI self-administra

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Novartis announces start of new secukinumab (AIN457) versus Stelara (ustekinumab) phase IIIb head-to-head psoriasis study at AAD 2014 Global phase IIIb head-to-head study of secukinumab versus Stelar

Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m. 5:00 p.m. EST More information Global Media Relations Eric Althoff Basel, Switzerland +41 61 324 7999 eric.althoff [a] novartis (p) com More information Investor Relations Switzerland investor.relations [a] novartis (p) com

Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m. 5:00 p.m. EST More information Global Media Relations Eric Althoff Basel, Switzerland +41 61 324 7999 eric.althoff [a] novartis (p) com More information Investor Relations Switzerland investor.relations [a] novartis (p) com

Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m. 5:00 p.m. EST More information Global Media Relations Eric Althoff Basel, Switzerland +41 61 324 7999 eric.althoff [a] novartis (p) com More information Investor Relations Switzerland investor.relations [a] novartis (p) com

Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Sandoz advances leading biosimilars pipeline by strengthening Immunology portfolio Global program marks Sandoz' sixth biosimilar molecule to enter Phase III testing Trial will support registration in

Novel inhaler approved for patients with asthma and COPD Approval follows completion of EU decentralized procedure (DCP) AirFluSal Forspiro strengthens Sandoz respiratory portfolio and reinforces com

In two Phase III studies, Jakavi reduced the risk of death and maintained spleen reductions at three years compared to conventional therapy and placebo Similar survival benefit seen in patients with and without high-risk mutations Separate analysis shows Jakavi may increase the probability of 10-year survival of myelofibrosis patients by more than 50% compared to conventional therapy Jakavi is the only JAK inhibitor approved in more than 50 coun

ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus Glivec Data demonstrated higher rates of early and deeper molecul

Data at ASH show increased scientific understanding of CTL019 and its potential role in the treatment of certain types of lymphocytic leukemia , , , Presentations include findings that 19 of 22 pediatric patients with acute lymphoblastic leukemia ( ALL) (86%) experienced complete remissions Novartis and Penn exclusive global collaboration to develop chimeric antigen receptor (CAR) technology is moving forward with the goal of expanding clinical

Study of LBH589 plus bortezomib and dexamethasone met primary endpoint of extending PFS compared to bortezomib plus dexamethasone and placebo LBH589 has potential to be the first in its class of anticancer agents available to patients with multiple myeloma Data will be presented at an upcoming medical congress and discussed with regulatory authorities worldwide Basel, December 6, 2013 - Novartis today announced that results of a Phase III trial

Africa's healthcare challenges are compounded as it begins to face a dual disease burden as non-communicable diseases rise In addition to existing corporate responsibility efforts such as its Malaria

Multiple studies evaluating deep molecular response with Tasigna versus Glivec in Ph+ CML patients Overall survival data from Jakavi Phase III trials in patients with the debilitating blood cancer, m

A natural antibiotic turns out to be a lethal weapon in the fight against tuberculosis. Scientists have discovered it has an unexpected dual action that dramatically reduces the probability that TB bacteria will become resistant. Technology has made it possible to synthesize increasingly targeted drugs.

Novartis takes action to strengthen portfolio and capital allocation, starts share buyback Blood transfusion diagnostics unit divested as part of ongoing portfolio management Reiterates optimal capit

Media Releases Biology Research Using Synchrotron Light Human Health Researchers elucidate how botulinum neurotoxin A binds to its protein receptor and thus provide a basis for the development of new drugs Botulinum neurotoxin A, better known as botox, is a highly dangerous toxin that causes paralysis in man that may prove fatal.

85% of subjects immunologically protected after receiving second dose of investigational cell culture vaccine when combined with proven MF59 adjuvant Vaccine now in large scale production highlightin

One-time single eye injection of Jetrea recognized as clinically and cost-effective treatment for eligible patients with vitreomacular traction, including macular hole Jetrea is the first and only ap

Group net sales up 4% (+6% cc ) to USD 14.3 billion in third quarter and up 2% (+4% cc) in first nine months; all divisions contributed to growth Negative currency impact of 6 percentage points

Omalizumab significantly reduced itch and hives caused by chronic spontaneous urticaria (CSU) as early as Week 1; benefit sustained over 24 weeks of active treatment Omalizumab 300 mg was nearly twice as effective in improving patients' quality of life within 12 weeks of treatment versus placebo ASTERIA I is the final omalizumab CSU registration study to be presented; regulatory applications were filed with EU and US authorities in Q3 2013 CSU i